MLEC (Moolec Science) EBITDA Margin % : -68.66% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Moolec Science EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Moolec Science's EBITDA for the three months ended in Sep. 2024 was $-1.07 Mil. Moolec Science's Revenue for the three months ended in Sep. 2024 was $1.56 Mil. Therefore, Moolec Science's EBITDA margin for the quarter that ended in Sep. 2024 was -68.66%.

Moolec Science EBITDA Margin % Historical Data

The historical data trend for Moolec Science's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moolec Science EBITDA Margin % Chart

Moolec Science Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

EBITDA Margin %

-5,717.24

-109.87

Moolec Science Quarterly Data
	Jun21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial							-87.13	-660.71	-29.72	-155.29	-68.66

Competitive Comparison of Moolec Science's EBITDA Margin %

For the Biotechnology subindustry, Moolec Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moolec Science's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moolec Science's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Moolec Science's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Moolec Science EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Moolec Science's EBITDA Margin % for the fiscal year that ended in Jun. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-6.18	/	5.625
	=	-109.87 %

Moolec Science's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-1.069	/	1.557
	=	-68.66 %

Moolec Science (NAS:MLEC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Moolec Science EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Moolec Science's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Moolec Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moolec Science SA (NAS:MLEC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

17, Boulevard F.W. Raiffeisen, Luxembourg, LUX, L-2411

Website

https://www.moolecscience.com

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.